

Supplementary Table 1. Comparison of clinical variables for total ER visits (treatment-related or unrelated)

Variable	ER visit (treatment-related or unrelated)	No ER visit	P-value
No. of patients	45	521	-
Age (yr)	60.2±14.2	57.4±13.8	0.205
Sex (male:female)	29:16 (64.4:35.6)	380:141 (72.9:27.1)	0.261
Comorbidity			
Smoking (current) (n=392)	19 (42.2)	188 (36.1)	0.390
Alcohol drinking (>moderate) (n=390)	23 (51.1)	212 (40.7)	0.577
Depression (n=368)	2 (4.4)	6 (1.2)	0.371
Body weight loss (>5% in 6 mo) (n=375)	8 (17.8)	58 (11.1)	0.638
Hypertension (n=401)	11 (24.4)	113 (21.7)	0.617
Diabetes (n=403)	4 (8.9)	51 (9.8)	0.434
ECOG PS 0:1:2:3 (n=138)	0:7:0:0 (0:15:6:0:0)	12:107:9:3 (2.3:20.5:1.7:0.6)	0.733
ASA PA classification I:II:III:IV (n=279)	1:7:23:5 (2.2:15.6:51.1:11.1)	14:71:137:21 (2.7:13.6:26.3:4.0)	0.087
Tumor subsite			
Oral cavity	15 (33.3)	118 (22.6)	0.152
Nasopharynx	1 (2.2)	91 (17.5)	<0.001
Oropharynx	2 (4.4)	78 (15.0)	0.003
Paranasal sinus, nasal cavity	6 (13.3)	58 (11.1)	0.680
Salivary gland	5 (11.1)	58 (11.1)	0.997
Larynx	8 (17.8)	51 (9.8)	0.183
Hypopharynx	8 (17.8)	31 (6.0)	0.049
Unknown primary	0	36 (6.9)	<0.001
T, N, and M classification			
Tx:Tis:T1:T2:T3:T4	2:1:10:14:11:7 (4.4:2.2:22.2:31.1:24.4:15.6)	54:14:175:125:79:74 (10.4:2.7:33.6:24.0:15.2:14.2)	0.038
Nx:N0:N1:N2:N3	2:27:6:9:1 (4.4:60.0:13.3:20.0:2.2)	33:265:65:107:51 (6.3:50.9:12.5:20.5:9.8)	0.164
Mx:M0:M1	2:43:0 (4.4:95.6:0)	24:462:35 (4.6:88.7:6.7)	0.061
TNM stage			
X:I:II:III:IV	1:10:9:10:15 (2.2:22.2:20.0:22.2:33.3)	11:167:87:82:174 (2.1:32.1:16.7:15.7:33.4)	0.409
Histologic type			
Squamous cell carcinoma	33 (73.3)	364 (69.9)	0.621
Mucoepidermoid carcinoma	7 (15.6)	48 (9.2)	0.264
Adenoid cystic carcinoma	1 (2.2)	34 (6.5)	0.086
Undifferentiated carcinoma	1 (2.2)	29 (5.6)	0.175
Adenocarcinoma	0	6 (1.2)	0.014
Lymphoma	0	1 (0.2)	0.318
Others ^{a)}	3 (6.7)	38 (7.3)	0.874
Treatment methods			
Surgery only	21 (46.7)	163 (31.3)	0.054
Surgery with adjuvant treatments	19 (42.2)	119 (22.8)	0.015
Surgery with RT	10 (22.2)	92 (17.7)	0.485
Surgery with CCRT	9 (20.0)	27 (5.2)	0.019
Curative non-surgical treatment	5 (11.1)	204 (39.2)	<0.001
Palliative treatment	0	35 (6.7)	<0.001

Values are presented as mean±standard deviation or number (%).

ER, emergency room; ECOG PS, Eastern Cooperative Oncology Group Performance Status Scale; ASA PS classification, American Society of Anesthesiologists Physical Status Classification System; RT, radiation treatments; CCRT, concurrent chemoradiation.

^{a)}Others: olfactory neuroblastoma, malignant melanoma, leiomyosarcoma, oncocytic carcinoma, embryonal rhabdomyosarcoma, anaplastic meningioma, high grade carcinoma, small cell neuroendocrine carcinoma, secretory carcinoma, undifferentiated pleomorphic sarcoma, mucinous eccrine carcinoma, spindle cell carcinoma, rhabdomyosarcoma, metastatic malignant melanoma, solitary plasmacytoma, lymphoepithelial carcinoma, epithelial-myoepithelial carcinoma.